The World Medical Association Statement on Genetics and Medicine

2006 ◽  
Vol 3 (5) ◽  

Abstract1 In recent years, the field of genetics has undergone rapid change and development. The areas of gene therapy and genetic engineering and the development of new technology have presented possibilities inconceivable only decades ago.2 The Human Genome Project opened new spheres of research. Its applications also proved useful to clinical care, by allowing physicians to utilize knowledge of the human genome in order to diagnose future disease as well as to individualize drug therapy (pharmacogenomics).3 Because of this, genetics has become an integral part of primary care medicine. Whereas at one time, medical genetics was devoted to the study of relatively rare genetic disorders, the Human Genome Project has established a genetic contribution to a variety of common diseases. It is therefore incumbent upon all physicians to have a working knowledge of the field.4 Genetics is an area of medicine with enormous medical, social, ethical and legal implications. The WMA has developed this statement in order to address some of these concerns and provide guidance to physicians. These guidelines should be updated in accordance with developments in the field of genetics.

2020 ◽  
Vol 8 ◽  
pp. 205031212091540 ◽  
Author(s):  
Rachele M Hendricks-Sturrup ◽  
Christine Y Lu

Genomic medicine is an emerging practice that followed the completion of the Human Genome Project and that considers genomic information about an individual in the provision of their clinical care. Large and start-up direct-to-consumer genetic testing companies like Ancestry, 23andMe, Luna DNA, and Nebula Genomics have capitalized on findings from the Human Genome Project by offering genetic health testing services to consumers without a clinical intermediary. Genomic medicine is thus further propelled by unprecedented supply and demand market forces driven by direct-to-consumer genetic testing companies. As government entities like the National Human Genome Research Institute question how genomics can be implemented into routine medical practice to prevent disease and improve the health of all members of a diverse community, we believe that stakeholders must first examine how and scenarios in which stakeholders can become motivated to share or receive genomic information. In this commentary, we discuss consumers three scenarios: satisfying personal curiosity, providing a social good, and receiving a financial return. We examine these motivations based on recent events and current avenues through which have engaged or can engage in genomic data sharing via private, secure (e.g. centralized genomic databases and de-centralized platforms like blockchain) and public, unsecure platforms (e.g. open platforms that are publicly available online). By examining these scenarios, we can likely determine how various stakeholders, such as consumers, might prefer to extract value from genomic information and how privacy preferences among those stakeholders might vary depending on how they seek to use or share genomic information. From there, one can recommend best practices to promote transparency and uphold privacy standards and expectations among stakeholders engaged in genomic medicine.


Author(s):  
Prachi Kalra

In 1866, when Mendel was carrying out his pea plant experiments in the monastery, nobody could predict what was to come. A genius whose ideas were appreciated after 34 years of their discovery, quite literally planted the seeds for the genetics that we’re familiar with, today. The important breakthrough was the completion of The Human Genome Project in 2003, which meant that scientists now had the genetic dictionary in their hands for an in-depth review of DNA and associated mutations. Eventually, the picture started to become clearer and our earlier speculation about the role of family history and environment in genetic disorders, now had concrete proof. The modern-day geneticist aims to identify, diagnose, and treat gene related conditions more efficiently than ever. This article surveys the different ways in which genetic disorders manifest themselves, their causative mutations, as well as early detection and treatment


Biomolecules ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 90
Author(s):  
Ryuji Hamamoto

The Human Genome Project, completed in 2003 by an international consortium, is considered one of the most important achievements for mankind in the 21st century [...]


Sign in / Sign up

Export Citation Format

Share Document